secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001104659-24-068007
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Brainstorm Cell Therapeutics temporary exception until Oct 21 for bid price compliance
--------------------------------------------------------------------------------

- Company received delisting notice on May 1 for failing $1 minimum bid price; appealed on May 2.
- Nasdaq granted temporary exception until Oct 21, 2024; must comply by then or face delisting.
- If not compliant by mid-August 2024, must execute reverse stock split no later than Oct 7, 2024.
- No assurance reverse split will achieve compliance; delisting risk persists if deadline missed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924068007/0001104659-24-068007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924068007/tm2416355d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-068007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer